Cancer treatment in the coronavirus disease pandemic

Zhang, Jiatao; Zhong, Wen‐Zhao; Wu, Yi‐Long

doi:10.1016/j.lungcan.2020.12.012

Cited by 3 publications

(3 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, the global outbreak caused by COVID-19 has become an unparalleled challenge, especially for the comprehensive treatment of patients with spinal tumors since December 2019 ( 1 , 27 ). It has been reported that severe complications were more likely to occur in elderly and fatal patients who have been diagnosed with malignant tumors ( 28 ). Therefore, vaccination against severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) may represent an unprecedented method of treatment in the fight against the pandemic.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real−clinical experience study

Wang

Zhou

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundEven if COVID-19 vaccine has gradually been adopted in the world, information of side effects and crosstalk in patients with spinal tumors is absent due to the exclusion from clinical research. In this research, we aimed to investigate the efficacy and safety for the patients with spinal tumors treated by denosumab.MethodsIn this retrospective research, 400 patients under treatment of denosumab against spinal tumors in real-clinical experience were grouped into two cohorts according to the treatment of COVID-19 vaccine. And linked hospital data, serum samples and unsolicited related adverse events had been collected from January 22nd 2021 to June 1st 2021 respectively.Results233 patients of all participants who received regular treatment of denosumab were vaccinated by mRNA or inactivated vaccine. Patients of metastatic disease and primary osseous spinal tumor showed similar distribution in both two groups. Over the study period, within 176 patients tested the status of serologic response of vaccine, 88(81.48%) and 41(87.23%) individuals injected one or two inactivated vaccines had effective antibody against SARS-CoV-2 infections. As 21 patients (85.71%) treated by mRNA vaccine did. Considering of the safety of vaccine, most common systemic adverse events were nausea or vomiting (45 events vs 23events). Interestingly, fewer participants in the vaccine group were statistically recorded in local adverse events than in the placebo group (16 events vs 33 events).ConclusionsOur initial real-clinical experience suggests that COVID-19 vaccines are likely safe and effective in in patients with spinal tumors receiving denosumab treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real−clinical experience study

Wang

Zhou

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Individuals with certain pre-existing conditions are particularly susceptible to COVID-19, and the relationship between COVID-19 and cancer has become a crucial and concerning issue. Patients with cancer are more susceptible to severe illness from COVID-19 than are those without cancer, which may be due to the presence of concurrent comorbidities, the inherent immunosuppressive characteristics of cancer, and the immunosuppression induced by systemic cancer treatments [ 2 ], with mortality rates as high as 25% being reported for patients with solid organ malignancies [ 3 ]. Respiratory failure is a severe complication of COVID-19 that typically occurs approximately 1 week after the onset of symptoms.…”

Section: Introductionmentioning

confidence: 99%

“…The risk of death from COVID-19 among cancer patients is influenced by age; male sex; performance status; comorbidities; and hematological malignancies [ 7 – 10 ]. Whether recent cancer treatment influence survival remains controversial [ 2 , 11 , 12 ]. Understanding the factors that increase the risk of death from COVID-19 is crucial for optimizing patient management and improving outcomes.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and outcomes among critically ill patients with cancer and COVID-19-related acute respiratory failure

Liao,

Shen,

Huang

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) has affected individuals worldwide, and patients with cancer are particularly vulnerable to COVID-19-related severe illness, respiratory failure, and mortality. The relationship between COVID-19 and cancer remains a critical concern, and a comprehensive investigation of the factors affecting survival among patients with cancer who develop COVID-19-related respiratory failure is warranted. We aim to compare the characteristics and outcomes of COVID-19-related acute respiratory failure in patients with and without underlying cancer, while analyzing factors affecting in-hospital survival among cancer patients. Methods We conducted a retrospective observational study at Taipei Veterans General Hospital in Taiwan from May to September 2022, a period during which the omicron variant of the severe acute respiratory syndrome coronavirus 2 was circulating. Eligible patients had COVID-19 and acute respiratory failure. Clinical data, demographic information, disease severity markers, treatment details, and outcomes were collected and analyzed. Results Of the 215 enrolled critically ill patients with COVID-19, 65 had cancer. The patients with cancer were younger and had lower absolute lymphocyte counts, higher ferritin and lactate dehydrogenase (LDH) concentrations, and increased vasopressor use compared with those without cancer. The patients with cancer also received more COVID-19 specific treatments but had higher in-hospital mortality rate (61.5% vs 36%, P = 0.002) and longer viral shedding (13 vs 10 days, P = 0.007) than those without cancer did. Smoking [odds ratio (OR): 5.804, 95% confidence interval (CI): 1.847–39.746], elevated LDH (OR: 1.004, 95% CI: 1.001–1.012), vasopressor use (OR: 5.437, 95% CI: 1.202–24.593), and new renal replacement therapy (OR: 3.523, 95% CI: 1.203–61.108) were independent predictors of in-hospital mortality among patients with cancer and respiratory failure. Conclusion Critically ill patients with cancer experiencing COVID-19-related acute respiratory failure present unique clinical features and worse clinical outcomes compared with those without cancer. Smoking, elevated LDH, vasopressor use, and new renal replacement therapy were risk factors for in-hospital mortality in these patients.

show abstract